

Methods: The Af-Sm co-culture was prepared on an 8-chambers Lab-Tek slide as described previously¹. Anti-GAG and anti-GM monoclonal antibodies produced at the *Aspergillus* Unit at Pasteur Institute of Paris, were used to focus on the 3D structure of GAG and GM in the ECM of the biofilm. These polysaccharides were analyzed by fluorescence confocal microscopy at 24 h.

Results and Conclusion: GM was found, as expected, in the hyphal Af cell wall but was very little in the ECM. GAG was also found in the cell wall but mainly formed a beautiful fibrillary network between the hyphae, showing the importance of this polysaccharide in cell-cell interaction and in the structuration of Af biofilm. GAG could be the surface receptor for Sm, which would promote strong adhesion between Sm and Af in the biofilm.

Sources:

1. Mellouli E et al. Front Microbiol. 2018;
2. Beauvais A et al. Microbiol Spectr. 2015;
3. Fontaine T et al. J Fungi. 2020;
4. Briard B et al. Mycologia 2016.

S2.4a

Pythiosis: An emerging disease in Hong Kong

Fanzcvs Vanessa Barrs^{1,2}, Fraser Hill³, May Tse⁴, Edmund Cheung⁴, Jane Gray⁵, Angeline Wong⁶, Karen Ng⁷, Wietz Botes⁸, Tony Matthews⁹, Jeanine Sandy⁹

¹Centre for Animal Health and Welfare, City University of Hong Kong, Hong Kong, China

²Department of Veterinary Clinical Sciences, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China

³Veterinary Diagnostic Laboratory, City University of Hong Kong, China

⁴Not for Profit Veterinary Clinic, Prince Edward, Hong Kong, China

⁵SPCA, Wan Chai, Hong Kong, China

⁶Wan Chai Animal Hospital, Wan Chai, Hong Kong, China

⁷Veterinary Medical Centre, City University of Hong Kong, Hong Kong

⁸Village Vets, Sai Kung, Hong Kong, China

⁹Acorn Veterinary Hospital, Sai Ying Pun, China

S2.4 Veterinary mycology research, September 21, 2022, 3:00 PM - 4:30 PM

Oomycosis is an emerging disease of humans and animals caused by oomycetes in the Stramenopiles-Alveolata-Rhizaria super group, mainly *Pythium insidiosum* and occasionally *Lagenidium giganteum* or *Paralagenidium* species. In surface freshwater, oomycetes produce motile biflagellate asexual zoospores with marked chemotactic attraction to epithelial surfaces of vertebrate hosts. Infection is the result of encystation and invasion of damaged skin or gastrointestinal mucosa.

Of ~ 4200 cases of pythiosis reported globally between 1980 and 2021 only ~ 20% involved humans while 80% involved animals, mainly horses, dogs, and cattle. Most human cases occur in India and Thailand, whereas most animal infections were reported in the United States and Brazil. Pythiosis has been reported in mainland China, but the burden of the disease is low and comprises <1% of overall cases in humans.

Neither pythiosis nor lagenidiosis has been previously reported in humans or animals in Hong Kong. From January 2018 to January 2022, the Veterinary Diagnostic Laboratory of City University of Hong Kong diagnosed 10 cases of oomycosis (5 canine, 5 feline) after identification of non-parallel walled, irregularly branching, and poorly septate hyphae in the center of necrotic regions of histological sections of formalin-fixed paraffin-embedded tissues (FFPET). Species identity was confirmed by PCR and sequencing of 28S rDNA from DNA extracts of FFPET. There were 8 cases of *P. insidiosum* and 2 of *L. giganteum* infection. Serum ELISA was positive for *Pythium* antibodies in 5/6 cases tested and negative for *Pythium/Lagenidium/Paralagenidium* antibodies in a German shepherd dog (GSD) with disseminated disease caused by *L. giganteum*.

Affected dogs were young to middle-aged at presentation (9 months to 5 years old). Two dogs had focal cutaneous infections, two had extensive gastrointestinal involvement, and the GSD had disseminated disease with cutaneous, mediastinal, and abdominal involvement.

Affected cats were young (8 weeks to 18 months) and presented with subcutaneous/cutaneous disease. Three cats had a distinctive perianal ring of bulging subcutaneous granulation tissue, including one that also had an ulcerated, proliferative and necrotic lesion involving two adjacent hind-limb digits. One cat had facial subcutaneous swelling with mandibular lymph node enlargement and the remaining cat presented with extensive circumferential swelling of one hind limb from the distal paw to the mid-stifle.

All cats tested negative for the Feline leukemia virus and Feline immunodeficiency virus. Traumatic or surgical wounds preceding infection were identified in a kitten caught in a rodent glue-trap with skin wounds, in a cat with facial involvement that had an injured globe surgically enucleated, and in a dog with cutaneous pythiosis that had chronic dermatitis.

Treatment data were available for one canine case. The GSD with lagenidiosis was treated with combination antimicrobial therapy including voriconazole, terbinafine, minocycline, and azithromycin. The dog responded poorly. Mefenoxam was substituted for voriconazole and hyperbaric oxygen therapy was administered. After initial response, the dog succumbed 4 months from diagnosis. We have had success with the treatment of four feline cases using combination therapy including surgical debridement, immunotherapy with a *Pythium* vaccine, and combinations of antifungal drugs (posaconazole and terbinafine), and/or antimicrobials (doxycycline/minocycline and azithromycin).

S2.4d

Combination antifungal effects of eugenol with voriconazole against *Candida tropicalis* and *Candida krusei* strains isolated from the genital tract of mares

Aghil Sharifzadeh¹, Hojjatollah Shokri², Donya Nikaein¹

¹Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran, Tehran, Iran

²Department of Pathobiology, Faculty of Veterinary Medicine, Amol University of Special Modern Technologies, Amol, Iran, Amol, Iran

S2.4 Veterinary mycology research, September 21, 2022, 3:00 PM - 4:30 PM

Objectives: The objective of the current study was to investigate the possibility that eugenol synergizes the antifungal effects of voriconazole on genital isolates of *Candida krusei* and *Candida tropicalis* from mares.

Methods: The antifungal activity of eugenol and voriconazole was evaluated using the broth microdilution assay (CLSI-M27-A3). The synergism of eugenol and voriconazole against genital *Candida* isolates was evaluated by the microdilution checkerboard method.

Results: Minimum inhibitory concentration (MIC) values for eugenol and voriconazole ranged from 400 to 800 µg/ml and 1 to 8 µg/ml, respectively, for *C. tropicalis* isolates, and from 200 to 400 µg/ml for eugenol and 2 to 16 µg/ml for voriconazole against *C. krusei* isolates. Eugenol decreased the arithmetic mean of MIC for voriconazole against *C. tropicalis* and *C. krusei* isolates from 2.66 to 0.46 µg/ml and 7.77 to 0.41 µg/ml respectively. The fractional inhibitory concentration index (FICI) values for the eugenol voriconazole combination ranged from 0.25 to 0.88 and 0.19 to 0.63 for *C. tropicalis* and *C. krusei* isolates respectively. A synergistic effect of eugenol in combination with voriconazole was observed for 83.3% of *C. tropicalis* and 77.7% of *C. krusei* isolates. The antagonistic activity was not seen in any of the isolates tested.

Conclusions: Eugenol showed fungistatic and fungicidal effects against genital *Candida* isolates and, in combination, synergized the antifungal effects of voriconazole. The eugenol-voriconazole combination can lay the foundation for a therapeutic approach against isolates in which azole resistance has increased over time.

S2.5a

Magnusiomyces spp.

Axel Hamprecht

University of Oldenburg, Oldenburg, Germany

S2.5 Rare yeasts, September 21, 2022, 3:00 PM - 4:30 PM

Magnusiomyces clavatus and *Magnusiomyces capitatus* are emerging yeasts with intrinsic resistance to many commonly used antifungal agents. Identification is difficult, and the determination of susceptibility patterns with commercial and reference methods is equally challenging. For this reason, few data on invasive infections by *Magnusiomyces* spp. are available. We,

therefore, determined the epidemiology and susceptibility of *Magnusiomyces* isolates from bloodstream infections (BSI) isolated in Germany and Austria from 2001 to 2020. A total of 34 *Magnusiomyces* BSI were analyzed; isolates were identified by internal transcribed spacer (ITS) sequencing and matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Antifungal susceptibility was determined by EUCAST broth microdilution and gradient tests. Of the 34 isolates, *M. clavatus* was more common ($n = 24$) than *M. capitatus* ($n = 10$). BSI by *Magnusiomyces* spp. were more common in men (62%) and mostly occurred in patients with hemato-oncological malignancies (79%). The highest *in vitro* antifungal activity against *M. clavatus/M. capitatus* was observed for voriconazole (MIC50, 0.03/0.125 mg/l), followed by posaconazole (MIC50, 0.125/0.25 mg/l). *M. clavatus* isolates showed overall lower MICs than *M. capitatus*. With the exception of amphotericin B, a low essential agreement between gradient test and microdilution was recorded for all antifungals (0%-70%). Both species showed distinct morphological traits on ChromAgar Orientation medium and Columbia blood agar, which can be used for differentiation if no MALDI-TOF MS or molecular identification is available. In conclusion, most BSI were caused by *M. clavatus*. The lowest MICs were recorded for voriconazole. Gradient tests demonstrated unacceptably low agreement and should preferably not be used for susceptibility testing of *Magnusiomyces* spp.

S2.5c

Exophiala spp.

Joerg Steinmann

Paracelsus Medical University Nuremberg, Nuremberg, Germany

S2.5 Rare yeasts, September 21, 2022, 3:00 PM - 4:30 PM

The black yeast *Exophiala dermatitidis* is an opportunistic pathogen, causing phaeoerythromycosis in immunosuppressed patients, chromoblastomycosis, and fatal infections of the central nervous system in otherwise healthy Asian patients. In addition, it is also regularly isolated from respiratory samples from cystic fibrosis patients, with rates varying between 1% and 19%. Melanin, as part of the cell wall of black yeasts, is one major factor known to contribute to the pathogenicity of *E. dermatitidis* and increased resistance against host defense and anti-infective therapeutics. Further virulence factors, e.g., the capability to adhere to surfaces and to form biofilm were reported.

S2.5d

Exploring multidrug resistance, fitness compensation, and collateral sensitivity in *Candida auris*: Fight fire with fire?

Hans Carolus¹, Dimitrios Sofras¹, Poppy Sephton-Clark², Louise Goossens¹, Alicia Chen¹, Siebe Pierson¹, Celia Lobo Romero¹, Ana Subotic¹, Jacques F. Meis^{3,4}, Christina A. Cuomo², Patrick Van Dijk¹

¹Laboratory of Molecular Cell Biology, Department of Biology, KU Leuven, Leuven, Belgium

²Broad Institute of MIT and Harvard, Cambridge, USA

³Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

⁴Centre of Expertise in Mycology Radboudum/CWZ, Nijmegen, The Netherlands

S2.5 Rare yeasts, September 21, 2022, 3:00 PM - 4:30 PM

Candida auris (*C. auris*) is a recently emerged human fungal pathogen of growing concern due to its ability to acquire extensive multidrug resistance (MDR) to all four antifungal drug classes. The unprecedented extent of MDR in *C. auris*, suggests accelerated resistance evolution, novel mechanisms of resistance, and/or potential fitness compensation. Despite being the first fungus to be officially considered an urgent antimicrobial resistance threat by the CDC (US), insights into the resistance mechanisms and evolutionary dynamics of *C. auris* are still scarce.

By using high-throughput *in vitro* experimental evolution with various antifungal drugs, we have obtained a library of resistant strains from four different clades. Through both genome and targeted sequencing, we have discovered novel mutations, especially for polyene resistance, which indicate new mechanisms of resistance and fitness compensation. For the validation of mutations, we have optimized a recyclable CRISPR/Cas9 tool for *C. auris* based on the *C. albicans* HIS-FLP system.

By mapping drug susceptibility responses of evolved strains across a library of several antifungals and repurposed drugs, we have discovered trends of cross-resistance and collateral sensitivity. Both phenomena have been extensively studied in tumors and bacteria but remain unexplored in fungi. In the light of these observations, we explore novel treatment schemes that prevent antifungal drug resistance development in *C. auris* and other pathogenic fungi.

S3.1a

Update in mycetoma control

Ahmed Hassan Fahal

The Mycetoma Research Center, University of Khartoum, Khartoum, Sudan

S3.1 Neglected implantation mycoses, September 21, 2022, 4:45 PM - 6:15 PM

Mycetoma is a badly neglected tropical disease, reported globally but endemic in many tropical and subtropical, and Sudan has the highest disease burden. Mycetoma epidemiological features remain uncharacterized. Hence, there is no preventive or control program for mycetoma worldwide. To reduce the disease burden and its socio-economic impacts on patients, families, communities, and the health system in the endemic regions, the Mycetoma Research Center, University of Khartoum, Sudan, WHO Collaborating Center on Mycetoma has adopted a unique holistic approach to management and mycetoma patients, and it gained a great experience on that.

In this presentation, we will share the MRC's experience in dealing with the patients at the endemic villages level, supporting the affected communities and collaborating with the local health authorities to improve the life quality of the affected patients.

S3.1d

High histoplasmosis incidence in kidney transplant recipients in Santa Fe city, Argentina

Guillermo Garcia Efron¹, Judith Ana Gaité³, Soledad Gamarra², Verónica Nuñez-Piñero³, Joaquín Agustí², Evelyn Cassini², Mariano Arriola³, José Hugo Paladini², Luis Gaité², Florencia Viches³

¹Laboratorio de Micología y Diagnóstico Molecular - CONICET, Santa Fe, Argentina

²Cátedra de Parasitología y Micología - FaC de Bioquímica - Universidad Nacional del Litoral, Santa Fe, Argentina


³Clinica de Nefrología, Urología y Enfermedades Cardiovasculares Urology and Cardiovascular Diseases Clinic, Santa Fe, Santa Fe, Argentina

S3.1 Neglected implantation mycoses, September 21, 2022, 4:45 PM - 6:15 PM

Objectives: Histoplasmosis is endemic in the central/northeast region of Argentina. No data on the incidence of Histoplasmosis are available in most countries. It is estimated that the incidence of this mycosis is low in solid organ transplant recipients. In endemic areas of the USA (Ohio), the incidence of histoplasmosis in kidney transplant recipients is 0.25%. The objectives of this work are to describe the epidemiology, clinical forms, and evolution of kidney transplant recipients' diagnoses with histoplasmosis in Santa Fe city, Argentina.

Methods: A retrospective study was carried out between July 2017 and July 2020 at the Nephrology, Urology, and Cardiovascular Diseases Clinic, Santa Fe (Argentina). Demographic, clinical, and laboratory data were obtained and analyzed. Histoplasmosis diagnosis was performed by means of histopathology (intracellular yeasts), recovery of Histoplasma spp. by culture, and/or positive nested PCR specific for Histoplasma Hc10 gene. No antigen detection method was available in Argentina at the time of the study.

Results: During the 36 months of the study, 225 kidney transplantations were performed. Out of these patients, 10 were diagnosed with histoplasmosis (4.44%). All the patients were Santa Fe province inhabitants. Patients' median age was 47 years old and 90% were male. A total of 9 patients (90%) presented the disseminated form of the disease and 1 the pulmonary form; 8 were recipients of their first transplant and 2 were second transplant recipients. All received thymoglobulin induction as immunosuppressive therapy. In all, 4 were diagnosed with histoplasmosis in their first-year post-transplantation (mostly 6-12 months) and the rest after 1-year post-transplantation. At the time of the histoplasmosis diagnosis, five patients presented glomerular filtration between 30 and 60 ml/min, two <15 ml/min, two between 30 and 15 ml/min, and only one with glomerular filtration >90 ml/min. A total of 7 retained graft function at the end of treatment, 3 lost the graft (1 due to death). Histoplasmosis



diagnosis was done in skin biopsies ($n = 4$), bone marrow ($n = 3$), CNS ($n = 1$), kidney graft ($n = 1$), and respiratory sample ($n = 1$). Laboratory diagnosis was done by histopathology, culture, and PCR in 3 cases (30%), by culture and PCR in 2 cases (20%) and by PCR alone in 5 cases (50%). Thus, all 10 patients showed positive nested PCR results. These results were informed within 24 h of receiving the samples. Cultures were positive in 5 cases and were considered positive on average after 26 days (ranging from 15 to 44 days) of incubation. All patients received amphotericin B as initial treatment. A total of 8 patients (80%) continued treatment with itraconazole and 1 with Voriconazole. Good response was observed in 9 patients.

Conclusion: We found a high incidence of histoplasmosis in kidney transplant recipients (10 times higher than reports from other endemic areas). Disseminated histoplasmosis was found in 90% of the patients. The same percentage of patients showed compromised graft function. The diagnosis was done after 1 year of transplantation in 60% of the cases. Diagnosis by histopathology/culture showed 50% sensitivity while nested PCR showed better sensitivity and diagnostic speed.

S3.2 Challenging clinical cases

Tanu Singhal¹, Ram Gopalakrishnan², Rajeev N. Soman³, Atul Patel⁴
¹Kokilaben Dhirubhai Ambani Hospital, Mumbai, Mumbai, India
²Apollo Hospitals, Chennai, India
³Department of Infectious Diseases, Deenanath Mangeshkar Hospital, Pune
⁴Department of Infectious Diseases, Sterling Hospitals, Ahmedabad, India
⁵Department of Microbiology, Sterling hospitals, Ahmedabad, India
 S3.2 Challenging clinical cases, September 21, 2022, 4:45 PM - 6:15 PM

A case of hepato-splenic-renal candidiasis will be discussed with the aim to track down the causative organism and its likely susceptibility. The role of BDG, selection of the antifungal agent, and duration of therapy will be discussed.

A case of an HIV-infected patient with cryptococcal meningitis, pulmonary infection, and pulmonary IRIS will be discussed. A case of *Candida auris* fungemia and organ infection in a liver transplant recipient who developed serially increasing MIC will be presented. The relevance of MIC, tentative breakpoints, and selection of antifungal agents based on PK/PD considerations will be discussed.

Talamycosis is usually seen in HIV-infected individuals from North East India. Here we discuss a 3-year-old girl with acute lymphoblastic leukemia from Western India who developed cavitary pneumonia and multiple brain abscesses due to talamycosis. The case posed significant management challenges pertaining to both the fungal infection and cancer.

Renal mucormycosis in healthy immunocompetent hosts is an entity generally reported only from India and China. We discuss the case of a previously healthy 3-month-old infant who presented with acute renal failure and renal mucormycosis. The case is unique with respect to the source of infection and management strategy.

Treatment of fungal infections involving the draining system of the kidney is challenging mainly due to limited antifungal drug penetration at the site of infection. Challenges in the treatment of amphotericin-resistant *Aspergillus terreus* pelvic/lyceal infections will be discussed.

CAPA is a well-known complication of coronavirus disease 2019 (COVID-19), but usually involves the lung alone and rarely disseminates when treated. This case illustrates a rare complication of COVID-19, namely endocarditis caused by *Aspergillus*.

Rhinosporidiosis is a well-known disease that usually involves mucosal surfaces in the head and neck. This case illustrates a rare occurrence, namely dissemination to multiple areas and mimicking the clinical presentation of other cutaneous mycoses.